Molecular approaches to improving general anesthetics

Anesthesiology Clinics

Volumn 28, Issue 4, 2010, Pages 761-771

  Forman, Stuart A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Drug development; Drug discovery; Etomidate; General anesthesia; Mechanism; Trends; Xenon

Indexed keywords

ALFAXALONE; ALKANE; ANESTHETIC AGENT; ARGON; BARBITURIC ACID DERIVATIVE; CARBOETOMIDATE; CYCLOPROPANE; ESMOLOL; ETOMIDATE; FOSPROPOFOL; HYPNOTIC AGENT; INHALATION ANESTHETIC AGENT; ISOFLURANE; KETAMINE; METHOXYCARBONYL ETOMIDATE; NITROUS OXIDE; PROPOFOL; REMIFENTANIL; UNCLASSIFIED DRUG; XENON;

ANESTHESIA INDUCTION; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; DEMOGRAPHY; DRUG DESIGN; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG SENSITIVITY; DRUG TARGETING; DRUG TRANSPORT; GENERAL ANESTHESIA; HUMAN; HYPOTENSION; HYPOTHERMIA; MEDICAL RESEARCH; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; POSTOPERATIVE NAUSEA AND VOMITING; RESPIRATION DEPRESSION; REVIEW;

ANESTHESIOLOGY; ANESTHETICS, GENERAL; ANIMALS; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 78149487923     PISSN: 19322275     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anclin.2010.08.004     Document Type: Review

References (59)

1. Campbell P.R. Population projections for states by age, sex, race, and Hispanic origin: 1995 to 2025 1996, U.S. Government Printing Office, Washington, DC, (U.S. Bureau of the Census, Population Division, PPL-47, 90 pages).
2. Russo C.A., Owens P., Steiner C., et al. Ambulatory surgery in U.S. hospitals, 2003 2007, Agency for Healthcare Research and Quality, Rockville (MD), (HCUP Fact Book No. 9. AHRQ Publication No. 07-0007, 64 pages).
3. Alkire M.T., Hudetz A.G., Tononi G. Consciousness and anesthesia. Science 2008, 322:876.
4. Franks N.P. General anaesthesia: from molecular targets to neuronal pathways of sleep and arousal. Nat Rev Neurosci 2008, 9:370.
5. Franks N.P., Lieb W.R. Do general anaesthetics act by competitive binding to specific receptors?. Nature 1984, 310:599.
6. Forman S.A., Miller K.W., Yellen G. A discrete site for general anesthetics on a postsynaptic receptor. Mol Pharmacol 1995, 48:574.
7. Mihic S.J., Ye Q., Wick M.J., et al. Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. Nature 1997, 389:385.
8. Franks N.P., Honore E. The TREK K2P channels and their role in general anaesthesia and neuroprotection. Trends Pharmacol Sci 2004, 25:601.
9. Solt K., Forman S.A. Correlating the clinical actions and molecular mechanisms of general anesthetics. Curr Opin Anaesthesiol 2007, 20:300.
10. Grasshoff C., Drexler B., Rudolph U., et al. Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des 2006, 12:3665.
11. Campagna J.A., Miller K.W., Forman S.A. Mechanisms of actions of inhaled anesthetics. N Engl J Med 2003, 348:2110.
12. Pratt M.B., Husain S.S., Miller K.W., et al. Identification of sites of incorporation in the nicotinic acetylcholine receptor of a photoactivatible general anesthetic. J Biol Chem 2000, 275:29441.
13. A receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog. J Neurosci 2006, 26:11599.
14. Stewart D.S., Desai R., Cheng Q., et al. Tryptophan mutations at azi-etomidate photo-incorporation sites on α1 or β2 subunits enhance GABAA receptor gating and reduce etomidate modulation. Mol Pharmacol 2008, 74:1687.
15. Jurd R., Arras M., Lambert S., et al. General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta3 subunit. FASEB J 2003, 17:250.
16. Reynolds D.S., Rosahl T.W., Cirone J., et al. Sedation and anesthesia mediated by distinct GABA(A) receptor isoforms. J Neurosci 2003, 23:8608.
17. Linden A.M., Sandu C., Aller M.I., et al. TASK-3 knockout mice exhibit exaggerated nocturnal activity, impairments in cognitive functions, and reduced sensitivity to inhalation anesthetics. J Pharmacol Exp Ther 2007, 323:924.
18. Sato Y., Kobayashi E., Murayama T., et al. Effect of N-methyl-D-aspartate receptor epsilon1 subunit gene disruption of the action of general anesthetic drugs in mice. Anesthesiology 2005, 102:557.
19. Petrenko A.B., Yamakura T., Kohno T., et al. Reduced immobilizing properties of isoflurane and nitrous oxide in mutant mice lacking the N-methyl-D-aspartate receptor GluR(epsilon)1 subunit are caused by the secondary effects of gene knockout. Anesth Analg 2010, 110:461.
20. Nagele P., Metz L.B., Crowder C.M. Nitrous oxide (N(2)O) requires the N-methyl-D-aspartate receptor for its action in Caenorhabditis elegans. Proc Natl Acad Sci U S A 2004, 101:8791.
21. Nagele P., Metz L.B., Crowder C.M. Xenon acts by inhibition of non-N-methyl-D-aspartate receptor-mediated glutamatergic neurotransmission in Caenorhabditis elegans. Anesthesiology 2005, 103:508.
22. Wagner R.L., White P.F., Kan P.B., et al. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 1984, 310:1415.
23. Corbett S.M., Montoya I.D., Moore F.A. Propofol-related infusion syndrome in intensive care patients. Pharmacotherapy 2008, 28:250.
24. Trapp S., Aller M.I., Wisden W., et al. A role for TASK-1 (KCNK3) channels in the chemosensory control of breathing. J Neurosci 2008, 28:8844.
25. Cotten J.F., Keshavaprasad B., Laster M.J., et al. The ventilatory stimulant doxapram inhibits TASK tandem pore (K2P) potassium channel function but does not affect minimum alveolar anesthetic concentration. Anesth Analg 2006, 102:779.
26. Paris A., Philipp M., Tonner P.H., et al. Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate. Anesthesiology 2003, 99:889.
27. Patel S., Wohlfeil E.R., Rademacher D.J., et al. The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol 2003, 139:1005.
28. Perouansky M., Hemmings H.C. Neurotoxicity of general anesthetics: cause for concern?. Anesthesiology 2009, 111:1365.
29. Newman S., Stygall J., Hirani S., et al. Postoperative cognitive dysfunction after noncardiac surgery: a systematic review. Anesthesiology 2007, 106:572.
30. Selnes O.A., Grega M.A., Bailey M.M., et al. Cognition 6 years after surgical or medical therapy for coronary artery disease. Ann Neurol 2008, 63:581.
31. Lee T.A., Wolozin B., Weiss K.B., et al. Assessment of the emergence of Alzheimer's disease following coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty. J Alzheimers Dis 2005, 7:319.
32. Selnes O.A., McKhann G.M. Neurocognitive complications after coronary artery bypass surgery. Ann Neurol 2005, 57:615.
33. Bianchi S.L., Tran T., Liu C., et al. Brain and behavior changes in 12-month-old Tg2576 and nontransgenic mice exposed to anesthetics. Neurobiol Aging 2008, 29:1002.
34. Culley D.J., Baxter M.G., Yukhananov R., et al. Long-term impairment of acquisition of a spatial memory task following isoflurane-nitrous oxide anesthesia in rats. Anesthesiology 2004, 100:309.
35. Rasmussen L.S., Johnson T., Kuipers H.M., et al. Does anaesthesia cause postoperative cognitive dysfunction? A randomised study of regional versus general anaesthesia in 438 elderly patients. Acta Anaesthesiol Scand 2003, 47:260.
36. Eckenhoff R.G., Johansson J.S., Wei H., et al. Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology 2004, 101:703.
37. Wan Y., Xu J., Ma D., et al. Postoperative impairment of cognitive function in rats: a possible role for cytokine-mediated inflammation in the hippocampus. Anesthesiology 2007, 106:436.
38. McDonagh D.L., Mathew J.P., White W.D., et al. Cognitive function after major noncardiac surgery, apolipoprotein E4 genotype, and biomarkers of brain injury. Anesthesiology 2010, 112:852.
39. Istaphanous G.K., Loepke A.W. General anesthetics and the developing brain. Curr Opin Anaesthesiol 2009, 22:368.
40. Loepke A.W., Soriano S.G. An assessment of the effects of general anesthetics on developing brain structure and neurocognitive function. Anesth Analg 2008, 106:1681.
41. Ikonomidou C., Bosch F., Miksa M., et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 1999, 283:70.
42. Ikonomidou C., Bittigau P., Ishimaru M.J., et al. Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome. Science 2000, 287:1056.
43. Lynch C., Baum J., Tenbrinck R. Xenon anesthesia. Anesthesiology 2000, 92:865.
44. Wilhelm S., Ma D., Maze M., et al. Effects of xenon on in vitro and in vivo models of neuronal injury. Anesthesiology 2002, 96:1485.
45. Ma D., Yang H., Lynch J., et al. Xenon attenuates cardiopulmonary bypass-induced neurologic and neurocognitive dysfunction in the rat. Anesthesiology 2003, 98:690.
46. Coburn M., Maze M., Franks N.P. The neuroprotective effects of xenon and helium in an in vitro model of traumatic brain injury. Crit Care Med 2008, 36:588.
47. Ma D., Williamson P., Januszewski A., et al. Xenon mitigates isoflurane-induced neuronal apoptosis in the developing rodent brain. Anesthesiology 2007, 106:746.
48. Dickinson R., Peterson B.K., Banks P., et al. Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor by the anesthetics xenon and isoflurane: evidence from molecular modeling and electrophysiology. Anesthesiology 2007, 107:756.
49. Coburn M., Baumert J.H., Roertgen D., et al. Emergence and early cognitive function in the elderly after xenon or desflurane anaesthesia: a double-blinded randomized controlled trial. Br J Anaesth 2007, 98:756.
50. Hocker J., Stapelfeldt C., Leiendecker J., et al. Postoperative neurocognitive dysfunction in elderly patients after xenon versus propofol anesthesia for major noncardiac surgery: a double-blinded randomized controlled pilot study. Anesthesiology 2009, 110:1068.
51. Loetscher P.D., Rossaint J., Rossaint R., et al. Argon: neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury. Crit Care 2009, 13:R206.
52. Cooke A., Anderson A., Buchanan K., et al. Water-soluble propofol analogues with intravenous anaesthetic activity. Bioorg Med Chem Lett 2001, 11:927.
53. Struys M.M., Fechner J., Schuttler J., et al. Requested retraction of six studies on the PK/PD and tolerability of fospropofol. Anesth Analg 2010, 110:1240.
54. Cotten J.F., Husain S.S., Forman S.A., et al. Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. Anesthesiology 2009, 111:240.
55. Cotten J.F., Forman S.A., Laha J.K., et al. Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function. Anesthesiology 2010, 112:637.
56. Liu R., Loll P.J., Eckenhoff R.G. Structural basis for high-affinity volatile anesthetic binding in a natural 4-helix bundle protein. FASEB J 2005, 19:567.
57. Vedula L.S., Brannigan G., Economou N.J., et al. A unitary anesthetic binding site at high resolution. J Biol Chem 2009, 284:24176.
58. Butts C.A., Xi J., Brannigan G., et al. Identification of a fluorescent general anesthetic, 1-aminoanthracene. Proc Natl Acad Sci U S A 2009, 106:6501.
59. Lea W.A., Xi J., Jadhav A., et al. A high-throughput approach for identification of novel general anesthetics. PLoS One 2009, 4:e7150.